SARASOTA, Fla., June 29 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation (OTC Pink Sheets: IBTY) (IBC), a company dedicated to new biotechnologies and innovations in the chemical industry, today announced the launch of the ALCHEMx Production Platforms(TM), a combination and integration of proprietary systems, intellectual property, licensed patents and the application of technologies to convert inexpensive raw materials into useful products with high commercial values.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060629/FLTH021LOGO )
The ALCHEMx Production Platforms(TM) are proprietary processes for the design, development, scale-up and optimization of specific chemical compounds that meet IBC's market, economic and technical criteria. IBC currently utilizes two Production Platforms: The ALCHEMx Biocatalysis Production Platform, which uses special proteins called designer enzymes to transform low value materials into high value compounds, and the ALCHEMx Biosynthesis Production Platform, which harnesses cells to convert simple raw materials into complex high value molecules. Both of these platforms integrate patents and intellectual property previously licensed by IBC from Oxford University and Rice University. The ALCHEMx Production Platforms(TM) also apply proprietary processes, technologies and applications including molecular and metabolomic engineering, fermentation, biotransformation, enzyme and protein engineering and product recovery.
The ALCHEMx Platforms enable IBC to design, develop and manufacture biological chemical compounds at significantly lower costs with substantially lower environmental impact compared to traditional methods and approaches. IBC's licensed patents and the ALCHEMx Production Platforms(TM) make possible the production of 40,000 plus commercially available compounds. These chemicals are used in a wide range of industries including: flavors and fragrances, fine chemicals, pharmaceuticals, cosmeceuticals, agricultural, biopesticides, bio-energy, biomaterials and biopolymer.
"Our focus is on transforming relatively low value raw materials through our proprietary production systems to generate valuable biologically generated products that are in high demand in the marketplace. We like to think of what we do, and how we do it, as 'modern alchemy' in that it can be compared favorably to the efforts of ancient alchemists -- hence, the ALCHEMx Production Platforms(TM)," said Gurinder Shahi, M.D., Ph.D., Chief Technologist & Chairman of IBC's Scientific Advisory Board.
"The ALCHEMx Production Platform(TM) is our commercialization engine. It represents our assembly line for bringing to market biologically produced, eco-friendly chemicals at lower costs. We currently have compounds in various stages of development and completion that we expect to roll out into the marketplace and are collaborating with our manufacturing and sales partners to identify and build IBC's product pipeline," said Andy Badolato, CEO of IBC.
On July 11 through July 14, senior members of IBC's Scientific and Management Team will be exhibiting the ALCHEMx Production Platforms(TM) at The World Congress on Industrial Biotechnology and Bioprocessing in Toronto, Canada. This industry conference will provide an opportunity to further showcase IBC's proprietary and patented technologies to potential partners, peers and industry media.
For a more information about the ALCHEMx Production Platforms(TM), please visit IBC's web site at http://www.industrialbiotechnology.com .
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high-value chemicals at significantly lower costs, with a higher purity and with a substantially lower environmental impact than traditional methods. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC seeks to bring to market new and established chemicals that are in high demand for use in the flavors and fragrances, fine chemicals, pharmaceuticals, cosmeceuticals, agricultural, biopesticides, bio-energy, biomaterials and biopolymer industries. IBC's pioneering and state-of-the-art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of "designer" enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled up to large commercial production levels. The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and seeks to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable, biological-based solutions and related intellectual property patents. For more information about Industrial Biotechnology Corporation, please visit its website at http://www.industrialbiotechnology.com .
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward- looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
SOURCE Industrial Biotechnology Corporation